-enzalutamide (xtandi) now approved in europe for the treatment of men with metastatic castration-resistant prostate cancer who are chemotherapy-naive

… adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or … outcomes for men with advanced prostate cancer who have not received chemotherapy …